Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis

Published:2023-04 Issue: Volume:115 Page:102512
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Filetti Marco,Lombardi Pasquale,Giusti Raffaele,Falcone Rosa,Scotte Florian,Giannarelli Diana,Carcagnì Antonella,Altamura Valeria,Scambia Giovanni,Daniele Gennaro

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference17 articles.

1. National Comprehensive Cancer Network. Antiemesis (Version 2.2022).

2. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy;Herrstedt;Support Care Cancer,2017

3. Antiemetics: ASCO Guideline Update;Hesketh;J Clin Oncol,2020

4. Update and new trends in antiemetic therapy: the continuing need for novel therapies;Feyer;Ann Oncol,2011

5. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices;Roscoe;J Pain Symptom Manage,2000

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis;Frontiers in Pharmacology;2024-09-13

2. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26

3. Acknowledging and addressing real-world challenges to treating immune-related adverse events;Journal for ImmunoTherapy of Cancer;2024-07

4. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice;Experimental Hematology & Oncology;2024-03-01

5. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study);JCO Global Oncology;2024-02